No reduction of HCV viral load in HIV patients co-infected with HCV genotype 1 during a 30 days course of nitazoxanide monotherapy

被引：4

作者：

Laufer, N. ^{[1
,2
,3
]}

Abusamra, L. ^{[2
,4
]}

Bolcic, F. ^{[3
]}

Gun, A. ^{[4
]}

Rolon, M. J. ^{[2
]}

Perez, H. ^{[2
]}

Krolewiecki, A. ^{[4
]}

Salomon, H. ^{[3
]}

Quarleri, J. ^{[3
]}

Cahn, P. ^{[2
,4
]}

机构：

[1] Univ Buenos Aires, Fac Med, CONICET, Ctr Nacl Referencia SIDA,Dept Microbiol, Buenos Aires, DF, Argentina

[2] Hosp Fernandez, Div Enfermedades Infecciosas, Buenos Aires, DF, Argentina

[3] Consejo Nacl Invest Cient & Tecn CONICET, Buenos Aires, DF, Argentina

[4] Fdn Huesped, Buenos Aires, DF, Argentina

来源：

ANTIVIRAL RESEARCH | 2011年 / 92卷 / 03期

关键词：

Nitazoxanide; HCV genotype 1; HIV/HCV co-infection; HCV treatment; CHRONIC HEPATITIS-C; RANDOMIZED CONTROLLED-TRIAL; ZAMBIAN CHILDREN; VIRUS; CRYPTOSPORIDIOSIS; PEGINTERFERON; TIZOXANIDE; INHIBITORS; RIBAVIRIN; THERAPY;

D O I：

10.1016/j.antiviral.2011.10.006

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

There are two new drugs approved and several in development for treatment of chronic HCV; among them nitazoxanide (NTZ). Twelve HIV/HCV genotype 1 co-infected patients were enrolled prospectively to receive a 30 days course of oral NTZ 500 mg bid. This therapy was well tolerated in this group of HIV patients co-infected with HCV genotype 1. Nevertheless no changes in HCV viral load were observed during treatment in none of the patients evaluated. This data suggests that despite the promising results reported for HCV genotype 4 mono-infected patients, NTZ exhibit poor activity as monotherapy in HIV/HCV co-infected patients with genotype 1. (C) 2011 Elsevier B.V. All rights reserved.

引用

页码：497 / 499

页数：3

共 50 条

[41] Phenotypic Characterization of Lymphocytes in HCV/HIV Co-infected Patients
Roe, Barbara
Coughlan, Suzie
Dean, Jonathan
Lambert, John S.
Keating, Shay
Norris, Suzanne
Bergin, Colm
Hall, William W.
VIRAL IMMUNOLOGY, 2009, 22 (01) : 39 - 47
[42] DEEP SEQUENCING REVEALS ACCUMULATION OF VIRAL VARIANTS IN HCV GENOTYPE 1 INFECTED PATIENTS DURING RIBAVIRIN MONOTHERAPY
Dietz, J.
Mihm, U.
Schelhorn, S-E
Fitting, D.
Susser, S.
Welker, M. W.
Teuber, G.
Manns, M.
Berg, T.
Lengauer, T.
Zeuzem, S.
Herrmann, E.
Sarrazin, C.
JOURNAL OF HEPATOLOGY, 2011, 54 : S540 - S541
[43] SPONTANEOUS CLEARANCE OR CHRONIC EVOLUTION OF HCV IN HIV/HCV CO-INFECTED PATIENTS - INFLUENCE OF THE IL28B GENOTYPE
Stenkvist, J.
Nystrom, J.
Falconer, K.
Sonnerborg, A.
Weiland, O.
JOURNAL OF HEPATOLOGY, 2013, 58 : S204 - S204
[44] HCV treatment patterns and utilization for HCV mono-infected and HCV-HIV co-infected patients in the veterans administration
Tam, HK
Phippard, AE
Baran, RW
Lanza, LL
Bozzette, SA
HEPATOLOGY, 2005, 42 (04) : 653A - 653A
[45] Provider-Based Barriers to HCV Treatment in HCV-HIV Co-Infected Patients
Surace, Lindsey T.
Wong, Michael
Baden, Rachel
GASTROENTEROLOGY, 2011, 140 (05) : S935 - S936
[46] Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients
Sherman, Kenneth E.
Guedj, Jeremie
Shata, Mohamed Tarek
Blackard, Jason T.
Rouster, Susan D.
Castro, Mario
Feinberg, Judith
Sterling, Richard K.
Goodman, Zachary
Aronow, Bruce J.
Perelson, Alan S.
SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (246)
[47] HAART and the risk for developing hyperglycaemia in HIV infected patients co-infected with HCV
Dragovic, G
Jevtovic, D
DRUG SAFETY, 2005, 28 (10) : 952 - 952
[48] HIV-1 Tropism and Liver Fibrosis in HIV-HCV Co-Infected Patients
Abravanel, Florence
Raymond, Stephanie
Pambrun, Elodie
Winnock, Maria
Bonnard, Philippe
Sogni, Philippe
Trimoulet, Pascale
Dabis, Francois
Salmon-Ceron, Dominique
Izopet, Jacques
PLOS ONE, 2012, 7 (11):
[49] HCV Viral Decline at Week 2 of Peg-IFN-Alpha-2a/RBV Therapy as a Predictive Tool for Tailoring Treatment in HIV/HCV Genotype 1 Co-Infected Patients
Rivero-Juarez, Antonio
Lopez-Cortes, Luis F.
Camacho, Angela
Torres-Cornejo, Almudena
Gordon, Ana
Ruiz-Valderas, Rosa
Torre-Cisneros, Julian
Pineda, Juan A.
Viciana, Pompeyo
Rivero, Antonio
PLOS ONE, 2014, 9 (06):
[50] Immune Biomarker Differences and Changes Comparing HCV Mono-Infected, HIV/HCV Co-Infected, and HCV Spontaneously Cleared Patients
Kushner, Lauren E.
Wendelboe, Aaron M.
Lazzeroni, Laura C.
Chary, Aarthi
Winters, Mark A.
Osinusi, Anu
Kottilil, Shyam
Polis, Michael A.
Holodniy, Mark
PLOS ONE, 2013, 8 (04):

← 1 2 3 4 5 →